Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

89Zr-DFO-REGN3767 in PET Scans in People with Diffuse Large B Cell Lymphoma

Trial Status: complete

This phase I/II trial evaluates 89Zr-DFO-REGN3767 in diagnosing patients with diffuse large B cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). 89Zr-DFO-REGN3767 is an antibody agent—an antibody to which a tiny amount of radioactivity is attached. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. The antibody part of 89Zr-DFO-REGN3767 attaches to the LAG-3 protein on tumor cells. The PET scans help doctors to see where 89Zr-DFO-REGN3767 goes in the body. 89Zr-DFO-REGN3767 may help researchers find tumors that make (express) LAG-3 and identify cancer patients who will benefit from cancer-fighting drugs that target LAG-3.